MAP2K1 and neoplasm: In CTCs from patient MEL31, with a BRAF V600E-mutated tumor, the BRAF V600E mutation was detected in the majority of the CTC analyzed (5/7) and another MAP2K1 N382H mutation was also detected in 2/7 CTCs (Figs. 2C and EV4B).